Anemia warrants treatment to improve survival in patients with heart failure receiving sacubitril–valsartan

Angiotensin inhibition remains a cornerstone for pharmacologic management of heart failure (HF), despite being associated with decreased hemoglobin (Hb) levels. To investigate the effect of anemia and its treatment on patients with HF treated with sacubitril–valsartan (S/V), we conducted a retrospec...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Tsun-Yu, Lee, Chii-Ming, Wang, Shih-Rong, Cheng, Yu-Yang, Weng, Shao-En, Hsu, Wan-Tseng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114364/
https://www.ncbi.nlm.nih.gov/pubmed/35581275
http://dx.doi.org/10.1038/s41598-022-11886-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114364/
https://www.ncbi.nlm.nih.gov/pubmed/35581275
http://dx.doi.org/10.1038/s41598-022-11886-2

Ejemplares similares